SAN LUIS OBISPO, California – October 16, 2003 – FzioMed, Inc. announced that Ronald F. Haynes, President and CEO of FzioMed, will present at the Rodman & Renshaw Techvest Healthcare Conference on Tuesday, October 21, 2003 at 6:20 pm. The conference will be held at the Long Wharf Marriott Hotel in Boston, MA and will be attended by healthcare industry leaders and experts from the investment and scientific communities.
Mr. Haynes will review FzioMed’s corporate activities and goals, including highlights from the company’s successful launch last year of its Oxiplex®/SP Adhesion Barrier Gel for spine surgery.
Rodman & Renshaw, Inc. is a privately held, full-service investment bank committed to the long-term success of emerging growth companies, primarily within the life sciences and technology sectors.
FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company’s patented Oxiplex platform technology. Oxiplex is an innovative polymer material that is formulated for a variety of indications and markets. Products include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products include Oxiplex/SP, the leading adhesion barrier gel for spine surgery. Other FzioMed products are in various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery materials.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.